MXCT vs ROL · rev $38.6M vs P/E 41, rev $3.39B
MaxCyte Inc (MXCT) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported ROL revenue for 2024-12-31 was $3.39B. Net income was $466.4M. Revenue was up 10.3% from 2023-12-31 to 2024-12-31. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
MXCT currently screens at market cap $124.3M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the MXCT and ROL stock pages for the full models.
Not investment advice.